<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Eden Research Plc — News on 6ix</title>
    <link>https://6ix.com/company/eden-research-plc</link>
    <description>Latest news and press releases for Eden Research Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 16 Apr 2026 13:59:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/eden-research-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e1f478dffbe2df126a24.webp</url>
      <title>Eden Research Plc</title>
      <link>https://6ix.com/company/eden-research-plc</link>
    </image>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/eden-research-plc/news/holdings-in-company-935</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/holdings-in-company-935</guid>
      <pubDate>Thu, 16 Apr 2026 13:59:00 GMT</pubDate>
      <description>Unicorn Asset Management Limited, through Unicorn AIM VCT plc, has notified Eden Research plc of a change in its major holding, crossing a threshold on April 13, 2026. The total voting rights held now stand at 7.54%, representing 60,576,923 voting rights, an increase from the previous notification of 5.19%. This change is attributed to an acquisition or disposal of voting rights and an event changing the breakdown of voting rights. The figures are based on a total of 613,362,994 voting rights in</description>
    </item>
    <item>
      <title>Completion of Conditional Placing and TVR</title>
      <link>https://6ix.com/company/eden-research-plc/news/completion-of-conditional-placing-and-tvr</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/completion-of-conditional-placing-and-tvr</guid>
      <pubDate>Fri, 10 Apr 2026 06:00:00 GMT</pubDate>
      <description>Eden Research plc has successfully completed its Conditional Placing, raising approximately £10.8 million in total through various offerings. Following the satisfaction of conditions, 190,000,000 New Ordinary Shares will be admitted to AIM on or around April 13, 2026. Post-admission, the company will have 803,362,994 ordinary shares in issue, with each carrying one vote, resulting in a total of 803,362,994 voting rights.
                Disclaimer*</description>
    </item>
    <item>
      <title>Satisfaction of Conditions of Conditional Placing</title>
      <link>https://6ix.com/company/eden-research-plc/news/satisfaction-of-conditions-of-conditional-placing</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/satisfaction-of-conditions-of-conditional-placing</guid>
      <pubDate>Wed, 08 Apr 2026 11:10:00 GMT</pubDate>
      <description>Eden Research plc has announced that all conditions for its Conditional Placing, initially detailed on February 2, 2026, have now been satisfied. The company, a leader in sustainable biopesticide and biocontrol technologies, will make a further announcement regarding the completion of the placing and its total voting rights. Cavendish Capital Markets Limited and Oberon Investments Limited acted as Joint Bookrunners for the placings.
                Disclaimer*</description>
    </item>
    <item>
      <title>Thymolflex EPA approval</title>
      <link>https://6ix.com/company/eden-research-plc/news/thymolflex-epa-approval</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/thymolflex-epa-approval</guid>
      <pubDate>Thu, 02 Apr 2026 06:00:00 GMT</pubDate>
      <description>Eden Research plc announced that its partner, Véto-pharma, has received regulatory approval from the US Environmental Protection Agency for Thymolflex®, a thymol-based treatment for Varroa mites in honey bees. This approval, following an April 2025 supply agreement, allows Thymolflex® to be used in integrated Varroa management strategies in the United States, offering beekeepers a naturally derived, flexible, and effective option to combat a significant threat to bee health.
                Disc</description>
    </item>
    <item>
      <title>Result of General Meeting and Total Voting Rights</title>
      <link>https://6ix.com/company/eden-research-plc/news/result-of-general-meeting-and-total-voting-rights-37</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/result-of-general-meeting-and-total-voting-rights-37</guid>
      <pubDate>Wed, 18 Feb 2026 09:40:00 GMT</pubDate>
      <description>Eden Research plc announced that all resolutions at its General Meeting were passed, approving the Placing, Subscription, and Retail Offer. Directors Lykele van der Broek, Sean Smith, Alex Abrey, and Derek McAllan subscribed for new ordinary shares totaling 1,125,000, 500,000, 500,000, and 250,000 respectively, at 4 pence per share. Following admission on or around February 19, 2026, the company will have 613,362,994 ordinary shares in issue, with each carrying one vote.
                Disclaim</description>
    </item>
    <item>
      <title>Result of Retail Offer</title>
      <link>https://6ix.com/company/eden-research-plc/news/result-of-retail-offer-37</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/result-of-retail-offer-37</guid>
      <pubDate>Thu, 05 Feb 2026 14:50:00 GMT</pubDate>
      <description>Eden Research plc announced the successful closure of its Retail Offer, raising approximately £0.2 million, with 3,760,473 Retail Offer Shares to be issued at 4.0 pence each. The company has conditionally raised a total of £10.8 million through its broader fundraising efforts. The Retail Offer is contingent on shareholder approval at the General Meeting on February 18, 2026, and the effectiveness of First Admission, expected around February 19, 2026, for 80,010,473 new Ordinary Shares. Second Ad</description>
    </item>
    <item>
      <title>Launch of Retail Offer</title>
      <link>https://6ix.com/company/eden-research-plc/news/launch-of-retail-offer-14</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/launch-of-retail-offer-14</guid>
      <pubDate>Mon, 02 Feb 2026 13:01:00 GMT</pubDate>
      <description>Eden Research plc is launching a retail offer of new ordinary shares at 4.0 pence per share, aiming to raise up to £500,000. This offer, priced at a 2.6% premium to the previous closing price of 3.9 pence, is part of a larger fundraising effort that could total £10.7 million. The net proceeds from the firm capital raising and the retail offer will be used to advance the development and commercialisation of its insecticide formulation and a new fungicide for potato disease. The retail offer is co</description>
    </item>
    <item>
      <title>Novellus+ Regulatory Authorisation in Chile</title>
      <link>https://6ix.com/company/eden-research-plc/news/novellus-regulatory-authorisation-in-chile</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/novellus-regulatory-authorisation-in-chile</guid>
      <pubDate>Fri, 09 Jan 2026 07:00:00 GMT</pubDate>
      <description>Eden Research plc has received its first regulatory authorisation in South America for its fungicide Novellus+™, approved by the Chilean Ministry of Agriculture for use on wine and table grapes to combat grey mould and powdery mildew. This significant development marks Eden&apos;s entry into Chile, a major agricultural market and one of the world&apos;s largest wine exporters, with Sipcam Chile SpA acting as the exclusive distributor. The Chilean crop protection market, valued at $735 million in 2022 and </description>
    </item>
    <item>
      <title>Mevalone Label Extension in France</title>
      <link>https://6ix.com/company/eden-research-plc/news/mevalone-label-extension-in-france</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/mevalone-label-extension-in-france</guid>
      <pubDate>Wed, 07 Jan 2026 07:00:00 GMT</pubDate>
      <description>Eden Research plc has received approval from French authorities for its biopesticide Mevalone to be used on grapes to combat downy and powdery mildew, a significant development given France&apos;s large grape market and increasing pressure on conventional fungicides. This label extension is estimated to have a potential peak revenue of up to €8 million per annum, though the company is not adjusting its current market guidance. The approval is timely due to tightened regulations on copper fungicides a</description>
    </item>
    <item>
      <title>Appointment of Syngenta as Distribution Partner</title>
      <link>https://6ix.com/company/eden-research-plc/news/appointment-of-syngenta-as-distribution-partner</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/appointment-of-syngenta-as-distribution-partner</guid>
      <pubDate>Thu, 18 Dec 2025 07:00:00 GMT</pubDate>
      <description>Eden Research plc has entered into an exclusive distribution agreement with Syngenta Crop Protection AG for its novel fungicide product, Evelta™, targeting professional uses in ornamental crops across several EU countries and the UK. Under the agreement, Eden will retain product registration ownership while Syngenta will invest in and provide biological efficacy data for registration purposes, subsequently supplying the finished product to professional ornamental growers. This partnership repres</description>
    </item>
    <item>
      <title>3LOGY Label Extension in Italy</title>
      <link>https://6ix.com/company/eden-research-plc/news/3logy-label-extension-in-italy</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/3logy-label-extension-in-italy</guid>
      <pubDate>Thu, 20 Nov 2025 07:00:00 GMT</pubDate>
      <description>Eden Research plc announced a significant label extension for its 3LOGY product in Italy, now approved for use on numerous new crops including legumes, avocado, carrot, radish, celery, and asparagus, in addition to controlling Botrytis and new diseases like powdery mildew and Sclerotinia. This expansion grows the addressable market in Italy by over twenty thousand hectares, positioning 3LOGY as a versatile biofungicide for a wider range of high-value crops and enhancing Eden&apos;s strategy of expand</description>
    </item>
    <item>
      <title>Ecovelex 2025 Approval in Italy</title>
      <link>https://6ix.com/company/eden-research-plc/news/ecovelex-2025-approval-in-italy</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/ecovelex-2025-approval-in-italy</guid>
      <pubDate>Mon, 17 Nov 2025 07:00:00 GMT</pubDate>
      <description>Eden Research plc has announced that its product Ecovelex™ 2025 has received temporary authorisation in Italy for use as a bird repellent seed treatment on maize for the 2026 growing season, providing farmers with continued access to this sustainable solution. This temporary approval, which follows similar permissions granted in 2023, allows Eden to sell Ecovelex while awaiting full EU-wide authorisation, expected in due course. Ecovelex is a replacement for conventional chemicals and is based o</description>
    </item>
    <item>
      <title>Director/PDMR Shareholdings</title>
      <link>https://6ix.com/company/eden-research-plc/news/directorpdmr-shareholdings-32</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/directorpdmr-shareholdings-32</guid>
      <pubDate>Wed, 17 Sep 2025 08:45:00 GMT</pubDate>
      <description>On September 17, 2025, Eden Research plc announced that a director, Sean Smith, purchased 390,624 ordinary shares at a price of 2.56 pence per share. Following this transaction, Sean Smith&apos;s total holdings amount to 3,059,768 ordinary shares, representing 0.57% of the company&apos;s issued share capital. The purchase was made on the London Stock Exchange.

                Disclaimer*</description>
    </item>
    <item>
      <title>Notice of Results</title>
      <link>https://6ix.com/company/eden-research-plc/news/notice-of-results-384</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/notice-of-results-384</guid>
      <pubDate>Mon, 15 Sep 2025 06:00:00 GMT</pubDate>
      <description>Eden Research plc will release its interim financial results for the six months ending June 30, 2025, on September 17, 2025. CEO Sean Smith and CFO Alex Abrey will host a live presentation via Investor Meet Company on the same day at 11:00 BST to discuss the Interim Results. The presentation is accessible to all existing and potential shareholders, who can submit questions in advance until September 16, 2025, at 09:00 BST or during the live presentation.

                Disclaimer*</description>
    </item>
    <item>
      <title>HSBC HOLDINGS PLC ANNOUNCES RESULTS OF ITS TENDER OFFERS FOR FOUR SERIES OF NOTES</title>
      <link>https://6ix.com/company/eden-research-plc/news/hsbc-holdings-plc-announces-results-of-its-tender-offers-for-four-series-of-notes-59</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/hsbc-holdings-plc-announces-results-of-its-tender-offers-for-four-series-of-notes-59</guid>
      <pubDate>Tue, 09 Sep 2025 10:52:00 GMT</pubDate>
      <description>HSBC Holdings plc (the &apos;Company&apos;, &apos;we&apos; or &apos;us&apos;) today announces the results of its previously announced four separate offers to purchase for cash any and all of the outstanding series of notes listed in the table below. We refer to the outstanding notes listed in the table below collectively as the &apos;Notes&apos; and separately as a &apos;series&apos; of Notes. We refer to each offer to purchase a series of Notes as an &apos;Offer&apos;, and collectively as the &apos;Offers&apos;.</description>
    </item>
    <item>
      <title>Result of AGM</title>
      <link>https://6ix.com/company/eden-research-plc/news/result-of-agm-1001</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/result-of-agm-1001</guid>
      <pubDate>Wed, 18 Jun 2025 12:40:00 GMT</pubDate>
      <description>Result of AGM.</description>
    </item>
    <item>
      <title>Ecovelex Partnership with Royal Holloway</title>
      <link>https://6ix.com/company/eden-research-plc/news/ecovelex-partnership-with-royal-holloway</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/ecovelex-partnership-with-royal-holloway</guid>
      <pubDate>Mon, 16 Jun 2025 06:00:00 GMT</pubDate>
      <description>Ecovelex Partnership with Royal Holloway.</description>
    </item>
    <item>
      <title>Notice of AGM</title>
      <link>https://6ix.com/company/eden-research-plc/news/notice-of-agm-531</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/notice-of-agm-531</guid>
      <pubDate>Tue, 27 May 2025 16:22:00 GMT</pubDate>
      <description>Notice of AGM.</description>
    </item>
    <item>
      <title>Mevalone Approval in California - Powdery Mildew</title>
      <link>https://6ix.com/company/eden-research-plc/news/mevalone-approval-in-california-powdery-mildew</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/mevalone-approval-in-california-powdery-mildew</guid>
      <pubDate>Tue, 13 May 2025 06:00:00 GMT</pubDate>
      <description>Mevalone Approval in California - Powdery Mildew.</description>
    </item>
    <item>
      <title>Investor Presentation via Investor Meet Company</title>
      <link>https://6ix.com/company/eden-research-plc/news/investor-presentation-via-investor-meet-company-108</link>
      <guid isPermaLink="true">https://6ix.com/company/eden-research-plc/news/investor-presentation-via-investor-meet-company-108</guid>
      <pubDate>Fri, 09 May 2025 06:00:00 GMT</pubDate>
      <description>Investor Presentation via Investor Meet Company.</description>
    </item>
  </channel>
</rss>